中国医院用药评价与分析2024，Vol.24Issue(11)：1355-1359,5.DOI:10.14009/j.issn.1672-2124.2024.11.015
基于数据挖掘探讨中医药治疗膜性肾病的用药规律
Medication Rules of Traditional Chinese Medicine in the Treatment of Membranous Nephro-pathy Based on Data Mining
摘要
Abstract
OBJECTIVE:To study the medication rules of traditional Chinese medicine in the treatment of membranous nephropathy,so as to provide references for the clinical treatment of membranous nephropathy.METHODS:CNKI,Wanfang Data and PubMed were retrieved to collect clinical studies of traditional Chinese medicine in the treatment of membranous nephropathy,and the data files were established.Excel 2019,Clementine 12.0 and SPSS 21.0 software were used to perform frequency statistics of syndrome types,usage frequency,classification,dosage,properties,tastes,and meridian tropism of drugs,association rule analysis,factor analysis and cluster analysis.RESULTS:A total of 179 traditional Chinese medicine compounds and 18 high-frequency drugs were included.Among them,Hedysarum Multijugum Maxim,Poria Cocos,Atractylodes Macrocephala Koidz,and Codonopsis Radix were the most frequently used,the most common efficacy classification was tonic drugs,the main properties was warm,and the main tastes was sweet,which was mostly attributed to the spleen meridians.Totally 16 drug combinations with high association strength were obtained by association rule analysis.Six common factors were extracted by factor analysis.Drugs could be divided into 4 groups by cluster analysis.CONCLUSIONS:The treatment of membranous nephropathy with traditional Chinese medicine mainly focuses on supplementing Qi,strengthening spleen,and tonifying kidney,replenish deficiency with sweet and warm,and the use of syndrome differentiation and combination of promoting blood circulation and resolving blood stasis,and promoting urination and draining dampness.关键词
膜性肾病/中医药/关联规则/因子分析/聚类分析Key words
Membranous nephropathy/Chinese medicine/Association rules/Factor analysis/Cluster analysis分类
医药卫生引用本文复制引用
朱正望,党雪,朱平生,车志英,苗明三..基于数据挖掘探讨中医药治疗膜性肾病的用药规律[J].中国医院用药评价与分析,2024,24(11):1355-1359,5.基金项目
河南中医药大学重点学科建设项目(No.15102040-2023-7) （No.15102040-2023-7）
河南中医药大学 2023 年度研究生科研创新能力提升计划(No.2023KYCX022) （No.2023KYCX022）
国家国际合作基地(No.国科外函[2016]65 号) （No.国科外函[2016]65 号）
